1. Exploiting sweet relief for preeclampsia by targeting autophagy-lysosomal machinery and proteinopathy.
- Author
-
Huang, Zheping, Cheng, Shibin, Jash, Sukanta, Fierce, Jamie, Agudelo, Anthony, Higashiyama, Takanobu, Hanna, Nazeeh, Nakashima, Akitoshi, Saito, Shigeru, Schuster, Jessica, Sharma, Surendra, and Padbury, James
- Subjects
Autophagy ,Pre-Eclampsia ,Female ,Humans ,Pregnancy ,Animals ,Lysosomes ,Trehalose ,Mice ,Trophoblasts ,Placenta ,Disease Models ,Animal - Abstract
The etiology of preeclampsia (PE), a severe complication of pregnancy with several clinical manifestations and a high incidence of maternal and fetal morbidity and mortality, remains unclear. This issue is a major hurdle for effective treatment strategies. We recently demonstrated that PE exhibits an Alzheimer-like etiology of impaired autophagy and proteinopathy in the placenta. Targeting of these pathological pathways may be a novel therapeutic strategy for PE. Stimulation of autophagy with the natural disaccharide trehalose and its lacto analog lactotrehalose in hypoxia-exposed primary human trophoblasts restored autophagy, inhibited the accumulation of toxic protein aggregates, and restored the ultrastructural features of autophagosomes and autolysosomes. Importantly, trehalose and lactotrehalose inhibited the onset of PE-like features in a humanized mouse model by normalizing autophagy and inhibiting protein aggregation in the placenta. These disaccharides restored the autophagy-lysosomal biogenesis machinery by increasing nuclear translocation of the master transcriptional regulator TFEB. RNA-seq analysis of the placentas of mice with PE indicated the normalization of the PE-associated transcriptome profile in response to trehalose and lactotrehalose. In summary, our results provide a novel molecular rationale for impaired autophagy and proteinopathy in patients with PE and identify treatment with trehalose and its lacto analog as promising therapeutic options for this severe pregnancy complication.
- Published
- 2024